Spex Capital, a London, UK-based early-stage investor in healthtech companies, launched a €100M global healthtech fund.
The fund will invest globally in early-stage healthtech ventures, from seed to Series A, up to €5M.
Founded by serial healthtech entrepreneur, Claudio D’Angelo, Spex Capital is a digital health and med-tech investment management firm specialized in investing in and advancing early-stage ventures to deliver innovations in healthcare systems globally.
Through an exclusive two-year partnership with MedCity, the life sciences cluster organisation for London, the firm benefits from connections to the NHS in England and extensive reach across the wider ecosystem. Joint activities include an international investment programme that contributes to the flow of around 1,000 healthcare companies developing breakthrough technologies every year. Spex Capital’s global reach will also be bolstered by the appointment of Brent Stackhouse, the Managing Director of Mount Sinai Ventures, to the team.
The fund is a designated Article 9 impact fund under the EU’s Sustainable Finance Disclosure Regulation (SFDR).
FinSMEs
27/02/2023